Neogen Corporation (NEOG)Healthcare | Medical Devices | Lansing, United States | NasdaqGS
11.66 USD
-0.08
(-0.681%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 11.66 |
Hot Take ↕ | Aug. 22, 2026, 5:58 a.m. EDT
The long-term investment case is severely compromised by a brutal multi-year decline; the stock has lost nearly 74% of its value over the last nine years, with the last two years showing consecutive negative returns. This trajectory indicates a structural deterioration where the market has permanently reassessed the business quality, rendering any current valuation metrics like P/E or book value misleading. While the company maintains a fortress-like balance sheet with minimal debt relative to equity and strong cash generation, the persistent inability to generate positive earnings and the shrinking revenue base suggest a failing core business model that cannot sustain a higher valuation. The short-term outlook remains murky; while the stock has recently bounced off its lows, the lack of earnings growth and the defensive positioning in options markets suggest this is likely a capitulation rally rather than a genuine trend reversal. Investors should avoid this security until there is clear, sustained evidence of a turnaround in both top-line growth and profitability. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.063614 |
| MSTL | 0.063778 |
| AutoARIMA | 0.067071 |
| AutoTheta | 0.088983 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 53.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 38.827 |
| Revenue per Share | 4.002 |
| Market Cap | 2,543,116,032 |
| Forward P/E | 30.68 |
| Beta | 1.77 |
| Profit Margins | -0.91% |
| Website | https://www.neogen.com |
As of Aug. 22, 2026, 5:58 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (7.5 and 10.0), creating a 'floor' scenario. Call interest is concentrated at the money and slightly out-of-the-money, suggesting a hope for a rebound to current levels rather than a breakout. The implied volatility is elevated, reflecting uncertainty about whether the stock can recover from its recent lows.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0815604 |
| Address1 | 620 Lesher Place |
| All Time High | 48.85 |
| All Time Low | 0.122253 |
| Ask | 14.68 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 1,451,700 |
| Average Daily Volume3 Month | 2,003,204 |
| Average Volume | 2,003,204 |
| Average Volume10Days | 1,451,700 |
| Beta | 1.77 |
| Bid | 8.44 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 9.614 |
| City | Lansing |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.66 |
| Current Ratio | 3.822 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 11.79 |
| Day Low | 11.43 |
| Debt To Equity | 38.827 |
| Display Name | Neogen |
| Earnings Call Timestamp End | 1,785,412,800 |
| Earnings Call Timestamp Start | 1,785,412,800 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,791,462,600 |
| Earnings Timestamp Start | 1,791,462,600 |
| Ebitda | 94,700,000 |
| Ebitda Margins | 0.1088 |
| Enterprise To Ebitda | 33.47 |
| Enterprise To Revenue | 3.642 |
| Enterprise Value | 3,169,633,024 |
| Eps Current Year | 0.31 |
| Eps Forward | 0.38 |
| Eps Trailing Twelve Months | -0.04 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.4106 |
| Fifty Day Average Change | 1.2494001 |
| Fifty Day Average Change Percent | 0.12001231 |
| Fifty Two Week Change Percent | 108.15604 |
| Fifty Two Week High | 12.85 |
| Fifty Two Week High Change | -1.1900005 |
| Fifty Two Week High Change Percent | -0.09260704 |
| Fifty Two Week Low | 4.9 |
| Fifty Two Week Low Change | 6.7599998 |
| Fifty Two Week Low Change Percent | 1.3795917 |
| Fifty Two Week Range | 4.9 - 12.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 619,882,200,000 |
| Float Shares | 217,098,750 |
| Forward Eps | 0.38 |
| Forward P E | 30.68421 |
| Free Cashflow | 69,500,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,636 |
| Fullday Change | -0.0799999 |
| Fullday Change Percent | -0.68143 |
| Fullday Price | 11.66 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.46932 |
| Gross Profits | 408,500,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0070499997 |
| Held Percent Institutions | 1.11414 |
| Implied Shares Outstanding | 218,106,005 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ir Website | http://www.neogen.com/Corporate/invest.html |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,780,185,600 |
| Last Split Date | 1,623,024,000 |
| Last Split Factor | 2:1 |
| Long Business Summary | Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan. |
| Long Name | Neogen Corporation |
| Market | us_market |
| Market Cap | 2,543,116,032 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_339683 |
| Most Recent Quarter | 1,780,185,600 |
| Net Income To Common | -7,900,000 |
| Next Fiscal Year End | 1,811,721,600 |
| Non Diluted Market Cap | 2,560,564,498 |
| Number Of Analyst Opinions | 3 |
| Open | 11.71 |
| Operating Cashflow | 83,200,000 |
| Operating Margins | 0.0137600005 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.66 |
| Phone | 517 372 9200 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 11.66 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 11.74 |
| Price Eps Current Year | 37.612904 |
| Price Hint | 2 |
| Price To Book | 1.2128146 |
| Price To Sales Trailing12 Months | 2.9217784 |
| Profit Margins | -0.00908 |
| Quick Ratio | 2.101 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.0799999 |
| Regular Market Change Percent | -0.68143 |
| Regular Market Day High | 11.79 |
| Regular Market Day Low | 11.43 |
| Regular Market Day Range | 11.43 - 11.79 |
| Regular Market Open | 11.71 |
| Regular Market Previous Close | 11.74 |
| Regular Market Price | 11.66 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,055,763 |
| Return On Assets | -0.00398 |
| Return On Equity | -0.00379 |
| Revenue Growth | -0.001 |
| Revenue Per Share | 4.002 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 218,106,005 |
| Shares Percent Shares Out | 0.045500003 |
| Shares Short | 9,933,588 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 10,786,299 |
| Short Name | Neogen Corporation |
| Short Percent Of Float | 0.0608 |
| Short Ratio | 4.47 |
| Source Interval | 15 |
| State | MI |
| Symbol | NEOG |
| Target High Price | 14.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 13.33333 |
| Target Median Price | 14.0 |
| Total Cash | 185,500,000 |
| Total Cash Per Share | 0.851 |
| Total Debt | 812,600,000 |
| Total Revenue | 870,400,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.20525 |
| Two Hundred Day Average Change | 2.45475 |
| Two Hundred Day Average Change Percent | 0.2666685 |
| Type Disp | Equity |
| Volume | 1,055,763 |
| Website | https://www.neogen.com |
| Zip | 48,912-1595 |